Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Trius’ (TSRX) Tedizolid Has Blockbuster Potential for MRSA Infections

Trius Therapeutics TSRX) is in late stage clinical development of its new antibiotic, tedizolid, for treatment of MRSA infections that have increased to epidemic levels in both the hospital and community settings. There are a number of companies competing in this market and a host of new products in development, but I see tedizolid as the most promising of the new products. I am projecting an introduction in the US in 2H, 2014 and see the potential for worldwide sales of $1+ billion in 2020. I estimate that this could lead to a market valuation of three times revenues at that time and a potential stock price of $60+.



Tagged as , , , , , , , , , , , + Categorized as Company Commentary


You must be logged in, or you must subscribe to post a comment.